Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

You may be eligible if

• Understand and voluntarily sign an informed consent form
• Able to adhere to the study visit schedule and other protocol requirements
• Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy
• Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug
• Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.